Written by Jo Halliday, CEO, Talking Medicines
Talking Medicines has taken a high-profile residency in Silicon Valley as part of the Scottish Government/SDI Market Booster Program, marking a significant step in accelerating our US growth. This initiative places us at the heart of the world’s leading tech and innovation hub, allowing us to deepen our engagement with industry pioneers and expand our reach within the US healthcare ecosystem.
After our first week in the Valley, here are some of the most common questions I’ve been asked—and my reflections on what this expansion means for Talking Medicines.
1. What motivated Talking Medicines to expand into the US market?
The US is the global leader in the pharmaceutical industry, making it a natural next step for our growth. We’ve already established a legal entity and headquarters in New York, bringing us closer to our customer base. Now, having successfully built our East Coast foundations, we’re looking westward—to Silicon Valley—to explore further opportunities, connect with tech leaders, and engage with new customers in the region.
2. How does Silicon Valley’s ecosystem align with Talking Medicines’ objectives?
Silicon Valley is a powerhouse for AI, data science, and innovation—the very core of what we do. Our US Market Booster residency is a strategic move to accelerate collaboration with leading tech innovators, enhance our patient-centric AI solutions, and explore new frontiers in health and wellness intelligence. The Valley offers a unique environment to scale our impact and connect with global thought leaders who are shaping the future of AI-driven healthcare.
3. What challenges do you anticipate in the US healthcare landscape?
The complexity of the US healthcare system presents both challenges and opportunities. At Talking Medicines, we bring deep expertise in navigating regulatory frameworks, understanding diverse HCP (healthcare professional) and patient demographics, and implementing structured processes to deliver actionable intelligence. These challenges also fuel innovation, allowing us to refine and adapt our solutions to meet the unique needs of the US market.
4. How does Talking Medicines differentiate itself from competitors?
What sets us apart is our ability to translate HCP and patient experiences into real-world intelligence for pharmaceutical marketers and agency strategists. By harnessing Advanced Data Science and AI, we provide unparalleled insights into patient and HCP sentiment—ultimately helping pharma companies create more effective, targeted marketing strategies and drive improved patient outcomes.
5. What are your immediate goals during this Silicon Valley tenure?
We have three key objectives for our time in Silicon Valley:
- Forge strategic partnerships with tech and healthcare leaders.
- Attract top US-based talent to strengthen our expertise.
- Engage with investors who share our vision for transforming pharmaceutical marketing through AI-driven insights.
Being in the Valley allows us to stay at the cutting edge of AI and healthcare innovation, ensuring that our solutions continue to lead in the industry.
6. How do you envision the future of Talking Medicines in the US?
Our vision is to be an integral part of the US healthcare ecosystem, providing pharma with the most advanced AI-powered intelligence tools to better understand and engage with HCPs and patients. By bridging the gap between real-world experiences and pharma decision-making, we aim to improve patient outcomes and contribute to a more patient-centered healthcare system.
Let’s Connect
This week has reinforced the scale of the opportunity ahead and our commitment to driving innovation at the intersection of AI and healthcare. We’re actively meeting with partners, investors, and industry leaders—if you’d like to connect, please reach out to:
Jo Halliday (CEO), Scott Crae (Partnerships), and Elizabeth Fairley (CDO/COO) are available for meetings—let’s discuss how we can collaborate to shape the future of AI-driven healthcare intelligence.
